After-Hours Stock Movers

At Home Group (NYSE: HOME) 46% HIGHER; reported revenue for the quarter of $515 million versus the consensus estimate of $360.87 million. Comparable store sales increase of approximately 42%.

JAKKS Pacific (NASDAQ: JAKK) 16.7% LOWER; reported Q2 adj. EPS of ($4.38), $0.32 worse than the analyst estimate of ($4.06). Revenue for the quarter came in at $78.8 million versus the consensus estimate of $79.5 million.

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) 16.4% HIGHER; Spring Bank and F-star Therapeutics, Limited (F-star), a privately-held clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announced that the companies have entered into a definitive share exchange agreement pursuant to which Spring Bank will, subject to stockholder approval, acquire all of the outstanding share capital of F-star in exchange for newly issued shares of Spring Bank in an all-stock transaction. The combined company, operating under the name F-star Therapeutics, Inc., will advance its immuno-oncology pipeline of multiple tetravalent bispecific antibody programs, as well as Spring Banks STING (STimulator of INterferon Gene) agonist, SB 11285, currently in a Phase 1/2 clinical trial.

Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) 15.2% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Spectrum.

Apache Corporation (Nasdaq: APA) 13.9% HIGHER; Apache and Total S.A. (NYSE: TOT) today announced a major oil discovery at the Kwaskwasi-1 well drilled offshore Suriname in Block 58. The well was drilled using the Noble Sam Croft with Apache as operator holding a 50% working interest and Total holding a 50% working interest.

Qualcomm (NASDAQ: QCOM) 12.2% HIGHER; reported Q3 EPS of $0.86, $0.15 better than the analyst estimate of $0.71. Revenue for the quarter came in at $4.89 billion versus the consensus estimate of $4.81 billion. Qualcomm sees Q4 2020 EPS of $1.05-$1.25, versus the consensus of $1.10. Qualcomm sees Q4 2020 revenue of $5.5-6.3 billion, versus the consensus of $5.78 billion.

Hologic (NASDAQ: HOLX) 8% HIGHER; reported Q3 EPS of $0.75, $0.37 better than the analyst estimate of $0.38. Revenue for the quarter came in at $822.9 million versus the consensus estimate of $616.69 million. Hologic sees Q4 2020 EPS of $0.95-$1.15, versus the consensus of $0.69. Hologic sees Q4 2020 revenue of $0.925-1.025 billion, versus the consensus of $0.8155 billion.

O'Reilly Automotive (NASDAQ: ORLY) 7% HIGHER; reported Q2 EPS of $7.10, $2.80 better than the analyst estimate of $4.30. Revenue for the quarter came in at $3.09 billion versus the consensus estimate of $2.62 billion. Second quarter comparable store sales increase of 16.2%, total sales growth of 19.4%.

Qorvo (NASDAQ: QRVO) 6.7% HIGHER; reported Q1 EPS of $1.50, $0.37 better than the analyst estimate of $1.13. Revenue for the quarter came in at $787 million versus the consensus estimate of $730.17 million. Qorvo sees Q2 2021 EPS of $1.90, versus the consensus of $1.44. Qorvo sees Q2 2021 revenue of $925-955 million, versus the consensus of $802.77 million.

Sturm Ruger (NYSE: RGR) 6% LOWER; reported Q2 EPS of $1.05, $0.18 worse than the analyst estimate of $1.23. Revenue for the quarter came in at $130.3 million versus the consensus estimate of $167.06 million.

PayPal (NASDAQ: PYPL) 5.8% HIGHER; reported Q2 EPS of $1.07, $0.19 better than the analyst estimate of $0.88. Revenue for the quarter came in at $5.26 billion versus the consensus estimate of $4.99 billion.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) 5.6% HIGHER; announced the expansion of its ongoing clinical trial of seclidemstat in patients with relapsed or refractory Ewing sarcoma to include additional select sarcomas that share a similar biology to Ewing sarcoma, also known as Ewing-related sarcomas. The planned amendment to the ongoing clinical trial will allow patients with Ewing-related sarcomas, which share a similar gene rearrangement to Ewing sarcoma, to enroll in the ongoing trial. Sarcomas of interest include myxoid liposarcoma, desmoplastic small round cell tumors and other sarcomas with FET family translocations, i.e. Ewing-related sarcomas.

ASGN Inc. (NYSE: ASGN) 5% HIGHER; reported Q2 EPS of $1.17, $0.30 better than the analyst estimate of $0.87. Revenue for the quarter came in at $936.8 million versus the consensus estimate of $898.89 million.

MKS Instruments (NASDAQ: MKSI) 4.9% HIGHER; reported Q2 EPS of $1.62, $0.44 better than the analyst estimate of $1.18. Revenue for the quarter came in at $544 million versus the consensus estimate of $491.82 million.

North American Construction (NYSE: NOA) 4.7% HIGHER; reported Q2 EPS of $0.45, $0.55 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $70.8 million versus the consensus estimate of $54.97 million.

Service Corp (NYSE: SCI) 4.6% HIGHER; reported Q2 EPS of $0.11, $0.13 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $820 million versus the consensus estimate of $708.31 million.

ServiceNow (NYSE: NOW) 4% LOWER; reported Q2 EPS of $1.23, $0.22 better than the analyst estimate of $1.01. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.05 billion.

Pilgrim's Pride (NASDAQ: PPC) 4% LOWER; reported Q2 EPS of $0.00, $0.09 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $2.82 billion versus the consensus estimate of $2.95 billion.

Genworth Financial (NYSE: GNW) 2.8% LOWER; reported Q2 EPS of ($0.04), $0.07 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $2.14 billion versus the consensus estimate of $1.98 billion.

Yum China (NYSE: YUMC) 2.7% LOWER; reported Q2 EPS of $0.35, $0.11 better than the analyst estimate of $0.24. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.96 billion.